An updated review of the treatment landscape for advanced gastrointestinal stromal tumors-Reference-Cited by-同舟云学术

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors

Published:2021-05-11 Issue:13 Volume:127 Page:2187-2195
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Patel Shreyaskumar R.¹^ORCID,Reichardt Peter²

Affiliation:

1. Department of Sarcoma Medical Oncology Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas

2. Oncology and Palliative Care, Sarcoma Center Helios Klinikum Berlin‐Buch Berlin Germany

Funder

Deciphera Pharmaceuticals

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33630

Reference75 articles.

1. Incidence of gastrointestinal stromal tumors in the United States from 2001‐2015: a United States cancer statistics analysis of 50 states;Patel N;Cureus,2019

2. Gastrointestinal stromal tumour

3. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

4. Epidemiology of Gastrointestinal Stromal Tumors in the Era of Histology Codes: Results of a Population-Based Study

5. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Entry of ZSWIM4 to the nucleus is crucial for its inhibition of KIT and BMAL1 in gastrointestinal stromal tumors;Cell & Bioscience;2024-06-29

2. RAF1 facilitates KIT signaling and serves as a potential treatment target for gastrointestinal stromal tumor;Oncogene;2024-05-17

3. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling;Molecular Carcinogenesis;2024-04-17

4. Clinicopathological Characteristics of Progressive Gastrointestinal Stromal Tumors and Heterogeneity Analyses of Secondary Mutations;2024

5. Research Progress of Avapritinib in the Treatment of Advanced Gastrointestinal Stromal Tumors with Mutation of Exon 18 of Platelet-Derived Growth Factor Receptor α;Advances in Clinical Medicine;2024